Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

727
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
727
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

952
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
952
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

909
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
909
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Supraventricular arrhythmias and left atrial evaluation in athletes by CMR: going beyond the left ventricle.

Journal of science and medicine in sport·2026
Same author

Effectiveness of Mediterranean diet for the primary prevention of cardiovascular diseases: A systematic review and meta-analysis featured in the Italian National Guidelines "La Dieta Mediterranea".

Nutrition (Burbank, Los Angeles County, Calif.)·2026
Same author

Myocardial Work Indices in Olympic Athletes: Sex-Specific Reference Values and the Impact of Sports Disciplines.

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography·2026
Same author

Gender-Specific Association of Cigarette Smoking with Spirometry and Cardiopulmonary Exercise Parameters in Elite Athletes-Impact of Cigarette Smoking in Elite Athletes.

Journal of clinical medicine·2026
Same author

Severe LVOT obstruction in HCM: effects on exercise capacity and outcomes from cardiopulmonary exercise testing combined with stress echocardiography.

European heart journal. Quality of care & clinical outcomes·2026
Same author

Exploring morpho-functional and cardiometabolic parameters in elite female athletes with extreme anthropometry.

The Physician and sportsmedicine·2026

Related Experiment Video

Updated: Jun 18, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.5K

Anthracyclines-Induced Cardiac Dysfunction: What Every Clinician Should Know.

Armando Ferrera1, Vincenzo Fiorentini1, Simone Reale1

  • 1Clinical and Molecular Medicine Department, Sapienza University of Rome, 00198 Rome, Italy.

Reviews in Cardiovascular Medicine
|July 30, 2024
PubMed
Summary

Anthracyclines improve cancer survival but can cause heart failure. This review details anthracycline cardiotoxicity, covering its mechanisms, diagnosis, and prevention strategies to manage patient care.

Keywords:
anthracyclinesanthracyclines-induced cardiotoxicitycardio-oncologycardiotoxicitychemotherapydrug-induced heart failure

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.8K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.8K

Related Experiment Videos

Last Updated: Jun 18, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.5K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.8K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.8K

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Chemotherapies have significantly improved cancer patient survival over the past two decades.
  • However, chemotherapy agents, particularly anthracyclines, can cause severe adverse effects, including cardiotoxicity.
  • Anthracycline-induced cardiotoxicity can lead to heart failure, limiting treatment efficacy and patient outcomes.

Purpose of the Study:

  • To review current evidence on anthracycline cardiotoxicity.
  • To explore the classification and molecular mechanisms of anthracycline-induced heart damage.
  • To provide an overview of diagnostic, therapeutic, and preventive strategies for managing cardiotoxicity.

Main Methods:

  • Literature review of existing studies on anthracyclines and cardiotoxicity.
  • Analysis of data regarding molecular mechanisms, diagnosis, and management.
  • Synthesis of current evidence on prevention and treatment approaches.

Main Results:

  • Anthracyclines are associated with significant cardiac risks, including heart failure.
  • Understanding the molecular pathways is crucial for identifying at-risk patients.
  • Early diagnosis and proactive management are key to mitigating cardiovascular damage.

Conclusions:

  • Prompt identification and management of anthracycline cardiotoxicity are essential.
  • Effective strategies can prevent treatment discontinuation and improve patient survival.
  • Managing cardiotoxicity enhances both short-term and long-term cardiovascular health in cancer patients.